Nigral GFRα1 infusion in aged rats increases locomotor activity, nigral tyrosine hydroxylase, and dopamine content in synchronicity

Molecular Neurobiology

Volumn 47, Issue 3, 2013, Pages 988-999

  Pruett, Brandon S ^a   Salvatore, Michael F ^a  

^a Louisiana State University School of Medicine Shreveport   (United States)

Author keywords

Aging; Bradykinesia; Dopamine; GFR 1; Parkinsonism; Striatum; Substantia nigra; Tyrosine hydroxylase

Indexed keywords

DOPAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR RECEPTOR ALPHA 1; RECOMBINANT GROWTH FACTOR; SERINE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; 3,4 DIHYDROXYPHENYLACETIC ACID; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR RECEPTOR;

AGING; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; IMMUNOREACTIVITY; IN VIVO STUDY; LOCOMOTION; MALE; MOTOR ACTIVITY; NEUROCHEMISTRY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; TREATMENT DURATION; ANIMAL; DRUG EFFECT; ENZYMOLOGY; FISCHER 344 RAT; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; METABOLISM; PHOSPHORYLATION; SOLUBILITY; SUBSTANTIA NIGRA;

3,4-DIHYDROXYPHENYLACETIC ACID; AGING; ANIMALS; DOPAMINE; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR RECEPTORS; INFUSIONS, INTRAVENTRICULAR; LOCOMOTION; MALE; PHOSPHORYLATION; RATS; RATS, INBRED F344; SOLUBILITY; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 84887313840     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-013-8397-7     Document Type: Article

References (60)

1. Granholm AC, Reyland M, Albeck D. (2000) Glial cell line-derived neurotrophic factor is essential for postnatal survival of midbrain dopamine neurons. J Neurosci 20:3182-3190
2. Pascual A, Hidalgo-Figueroa M, Piruat JI et al (2008) Absolute requirement of GDNF for adult catecholaminergic neuron survival. Nat Neurosci 11:755-761
3. Nevalainen N, Chermenina M, Rehnmark A et al (2010) Glial cell line-derived neurotrophic factor is crucial for long-term maintenance of the nigrostriatal system. Neuroscience 171:1357-1366
4. Boger HA, Middaugh LD, Huang P et al (2006) A partial GDNF depletion leads to earlier age-related deterioration of motor function and tyrosine hydroxylase expression in the substantia nigra. Exp Neurol 202:336-347
5. Boger HA, Middaugh LD, Zaman V et al (2008) Differential effects of the dopamine neurotoxin MPTP in animals with a partial deletion of the GDNF receptor, GFR alpha1, gene. Brain Res 1241:18-28
6. Zaman V, Boger HA, Granholm AC et al (2008) The nigrostriatal dopamine system of aging GFRalpha-1 heterozygous mice: neuro-chemistry, morphology and behavior. Eur J Neurosci 28:1557-1568
7. Hudson J, Granholm AC, Gerhardt GA et al (1995) Glial cell line-derived neurotrophic factor augments midbrain dopaminergic circuits in vivo. Brain Res Bull 36:425-432
8. Bowenkamp KE, Lapchak PA, Hoffer B.J., Bickford P.C. (1996) Glial cell line-derived neurotrophic factor reverses motor impairment in 16-17 month old rats. Neurosci Lett 211:81-84
9. Hebert MA, Gerhardt G.A. (1997) Behavioral and neurochemical effects of intranigral administration of glial cell line-derived neurotrophic factor on aged Fischer 344 rats. J Pharmacol Exp Ther 282:760-768
10. Maswood N, Grondin R, Zhang Z et al (2002) Effects of chronic intraputamenal infusion of glial cell line-derived neurotrophic factor (GDNF) in aged Rhesus monkeys. Neurobiol Aging 23:881-889
11. Grondin R, Cass WA, Zhang Z et al (2003) Glial cell line-derived neurotrophic factor increases stimulus-evoked dopamine release and motor speed in aged rhesus monkeys. J Neurosci 23:1974-1980
12. Hoffer BJ, Hoffman AF, Bowencamp KE et al (1994) Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci Lett 182:107-111
13. Gash DM, Zhang Z, Ovadia A et al (1996) Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380:252-255
14. Aoi M, Date I, Tomita S., Ohmoto T. (2000) The effect of intra-striatal single injection of GDNF on the nigrostriatal dopaminergic system in hemiparkinsonian rats: behavioral and histological studies using two different dosages. Neurosci Res 36:319-325
15. Connor B, Kozlowski DA, Unnerstall JR et al (2001) Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration. Exp Neurol 169:83-95
16. Grondin R, Zhang Z, Ai Y et al (2002) Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. Brain 125:2191-2201
17. Gill SS, Patel NK, Hotton GR et al (2003) Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 9:589-595
18. Slevin JT, Gerhardt GA, Smith CD et al (2005) Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg 102:216-222
19. Georgievska B, Kirik D, Bjorklund A. (2004) Overexpression of glial cell line-derived neurotrophic factor using a lentiviral vector induces time- and dose-dependent downregulation of tyrosine hy-droxylase in the intact nigrostriatal dopamine system. J Neurosci 24:6437-6445
20. Salvatore MF, Zhang JL, Large DM et al (2004) Striatal GDNF administration increases tyrosine hydroxylase phosphorylation in the rat striatum and substantia nigra. J Neurochem 90:245-254
21. Salvatore MF, Gerhardt GA, Dayton R.D., Klein RL, Stanford J.A. (2009) Bilateral effects of unilateral GDNF administration on dopamine- and GABA-regulating proteins in the rat nigrostriatal system. Exp Neurol 219:197-207
22. Gerhardt GA, Cass WA, Huettl P et al (1999) GDNF improves dopamine function in the substantia nigra but not the putamen of unilateral MPTP-lesioned rhesus monkeys. Brain Res 817:163-171
23. Trevitt JT, Carlson BB, Nowend K, Salamone J.D. (2004) Substan-tia nigra pars reticulata is a highly potent site of action for the behavioral effects of the D1 antagonist SCH23390 in the rat. Psychopharmacology 156:32-41
24. Bergquist F, Shahabi HN, Nissbrandt H. (2003) Somatodendritic dopamine release in rat substantia nigra influences motor performance on the accelerating rod. Brain Res 973:81-91
25. Andersson DR, Nissbrandt H, Bergquist F. (2006) Partial depletion of dopamine in substantia nigra impairs motor performance without altering striatal dopamine neurotransmission. Eur J Neurosci 24:617-624
26. Salvatore MF, Pruett BS, Spann S.L., Dempsey C. (2009) Aging reveals a role for nigral tyrosine hydroxylase ser31 phosphorylation in locomotor activity generation. PLoS One 4:8466
27. Lang AE, Gill SS, Patel NK et al (2006) Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson's disease. Ann Neurol 59:459-466
28. Decressac M, Ulusoy A, Mattson B et al (2011) GDNF fails to exert neuroprotection in a rat a-synuclein model of Parkinson's disease. Brain 134:2302-2311
29. Jing S, Wen D, Yu Y et al (1996) GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF. Cell 85:1113-1124
30. Treanor JJ, Goodman L, de Sauvage F et al (1996) Characterization of a multicomponent receptor for GDNF. Nature 382:80-83
31. Mijatovic J, Airavaara M, Planken A et al (2007) Constitutive Ret activity in knock-in multiple endocrine neoplasia type B mice induces profound elevation of brain dopamine concentration via enhanced synthesis and increases the number of TH-positive cells in the substantia nigra. J Neurosci 18:4799-4809
32. Sariola H, Saarma M. (2003) Novel functions and signaling pathways for GDNF. J Cell Sci 116:3855-3862
33. Tomac AC, Widenfalk J, Lin LFH et al (1995) Retrograde axonal transport of glial cell line-derived neurotrophic factor in the adult nigrostriatal system suggests a trophic role in the adult. Proc Natl Acad Sci A 92:8274-8278
34. Tomac AC, Grinberg A, Huang SP et al (2000) Gial cell line-derived neurotrophic factor receptor α1 availability regulates glial cell line-derived neurotrophic factor signaling: evidence from mice carrying one or two mutated alles. Neuroscience 95:1011-1023
35. Matsuo A, Nakamura S, Akiguchi I. (2000) Immunohistochemical localization of glial cell line-derived neurotrophic factor family receptor α-1 in the rat brain: confirmation of expression in various neuronal systems. Brain Res 859:57-71
36. Paratcha G, Ledda F, Baars L et al (2001) Released GFRalpha1 potentiates downstream signaling, neuronal survival, and differentiation via a novel mechanism of recruitment of c-Ret to lipid rafts. Neuron 29:171-184
37. Pruett BS, Salvatore M.F. (2010) GFR alpha-1 receptor expression in the aging nigrostriatal and mesoaccumbens pathways. J Neurochem 115:707-715
38. Salvatore MF, Pruett BS, Dempsey C, Fields V. (2012) Comprehensive profiling of dopamine regulation in substantia nigra and ventral tegmental area. JOVE (66), e4171, doi: 10.3791/4171
39. Salvatore MF, Pruett B.S. (2012) Dichotomy of tyrosine hydroxylase and dopamine regulation between somatodendritic and terminal field areas of nigrostriatal and mesoaccumbens pathways. PLoS One 7(1):29867
40. Haycock JW, Ahn NG, Cobb M.H., Krebs E.G. (1992) ERK1 and ERK2, two microtubule-associated protein 2 kinases, mediate the phosphorylation of tyrosine hydroxylase at serine-31 in situ. Proc Natl Acad Sci A 89:2365-2369
41. Trupp M, Scott R, Whittemore S.R., Ibanez C.F. (1999) Retdependent and -independent mechanisms of glial cell line-derived neurotrophic factor signaling in neuronal cells. J Biol Chem 274:20885-20894
42. Besset V, Scott RP, Ibanez C.F. (2000) Signaling complexes and protein-protein interactions involved in the activation of the Ras and phosphatidylinositol 3-kinase pathways by the c-Ret receptor tyrosine kinase. J Biol Chem 275:39159-39166
43. Salvatore MF, Waymire JC, Haycock J.W. (2001) Depolarization-stimulated catecholamine biosynthesis: involvement of protein kinases and tyrosine hydroxylase phosphorylation sites in situ. J Neurochem 79:349-360
44. Salvatore MF, Davis RW, Arnold J.C., Chotibut T. (2012) Transient striatal GLT-1 blockade increases EAAC1 expression, glutamate reuptake, and decreases tyrosine hydroxylase phosphorylation at ser(19). Exp Neurol 234:428-436
45. 2+ channels and transmitter release. Neuron 32:99-112
46. Rosenblad C, Georgievska B, Kirik D. (2003) Long-term striatal overexpression of GNDF selectively downregulates tyrosine hydrox-ylase in the intact nigrostriatal dopamine system. Eur J Neurosci 17:260-270
47. Haycock JW, Becker L, Ang L et al (2003) Marked disparity between age-related changes in dopamine and other presynaptic dopaminergic markers in human striatum. J Neurochem 87:574-585
48. Salvatore MF, Ai Y, Fischer B et al (2006) Point source concentration of GDNF may explain failure of phase II clinical trial. Exp Neurol 202:497-505
49. Lei Z, Jiang Y, Li T et al (2011) Signaling of glial cell line-derived neurotrophic factor and its receptor GFRalpha1 induce Nurr1 and Pitx3 to promote survival of grafted midbrain-derived neural stem cells in a rat model of Parkinson disease. J Neuropathol Exp Neurol 70:736-747
50. Collier TJ, Ling ZD, Carvey PM et al (2005) Striatal trophic factor activity in aging monkeys with unilateral MPTP-induced parkin-sonism. Exp Neurol 191(SUPPL. 1):S60-S67
51. Dass B, Kladis T, Chu Y., Kordower J.H. (2006) RET expression does not change with age in the substantia nigra pars compacta of rhesus monkeys. Neurobiol Aging 27:857-861
52. Alladi PA, Mahadevan A, Shankar SK et al (2010) Expression of GDNF receptors GFRalpha1 and RET is preserved in substantia nigra pars compacta of aging Asian Indians. J Chem Neuroanat 40:43-52
53. Bennett DA, Beckett LA, Murray AM et al (1996) Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 334:71-76
54. Prettyman R (1998) Extrapyramidal signs in cognitively intact elderly people. Age Ageing 27:557-560
55. Bartus RT, Brown L, Wilson A et al (2011) Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease. Neurobiol Dis 44:38-52
56. Sarabi A, Hoffer BJ, Olson L, Morales M. (2001) GFRalpha-1 mRNA in dopaminergic and nondopaminergic neurons in the substantia nigra and ventral tegmental area. J Comp Neurol 441:106-117
57. Franke B, Figiel M, Engele J. (1998) CNS glia are targets for GDNF and neurturin. Histochem Cell Biol 110:595-601
58. Remy S, Naveilhan P, Brachet P., Neveu I. (2001) Differential regulation of GDNF, neurturin, and their receptors in primary cultures of rat glial cells. J Neurosci Res 64:242-251
59. Honda S, Nakajima K, Nakamura Y et al (1999) Rat primary cultured microglia express glial cell line-derived neurotrophic factor receptors. Neurosci Lett 275:203-206
60. Salvatore MF (2012) Targeting tyrosine hydroxylase to improve bradykinesia. In: Dushanova J (ed) Mechanisms in Parkinson's disease-models and treatments. InTech http://www.intechopen.com/books/mechanisms-in-parkinson-s- disease-models-and-treatments/targeting-tyrosine-hydroxylase-to-improve- bradykinesia